International Scientific Recognition for NFL Biosciences: 3 Presentations Selected at the 2026 SRNT-Europe Conference, Including an Oral Presentation on NFL-102

About this update from Nfl Biosciences Sa

MONTPELLIER, France, July 07, 2026 --( BUSINESS WIRE )--Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, announces today that three scientific communications dedicated to its drug candidates NFL-101 and NFL-102 have been accepted for presentation at the 2026 Annual SRNT-Europe Conference, which will be held in Paris from 21 to 23 September 2026. SRNT-Europe is the European chapter of the Society for Research on Nicotine and Tobacco, the leading international scientific organization dedicated to nicotine and tobacco research. These communications include an oral presentation on NFL-102 and two posters dedicated to NFL-101 and NFL-102. They are part of NFL Biosciences' strategy to strengthen the scientific recognition of its smoking cessation programs and to share its work with the international community specialized in nicotine and tobacco research. Oral presentation dedicated to the effects of NFL-102 on neuroimmune and signaling pathways Title : " Combined brain PET imaging and proteomics in a mouse model of tobacco-smoke exposure reveal the region-specific effects of NFL-102 on neuroimmune and signaling pathways ". This presentation will cover work combining brain positron emission tomography (PET) imaging and proteomic analyses in a mouse model of tobacco-smoke exposure. This work aims to further characterize the effects of NFL-102 on neuroimmune and signaling pathways involved in the mechanisms of nicotine dependence. The presentation will be delivered by Nicolas Tournier, Director of the Biomaps unit at CEA Paris-Saclay. The selection of this communication as an oral presentation represents an important signal of the scientific interest generated by NFL-102 and its original approach, based on the exploration of interactions between tobacco exposure, the immune system and the central nervous system. Two posters on the NFL-101 biomarker and the design of the TONIC trial

View stock analysis, news, and events for Nfl Biosciences Sa